Klin Farmakol Farm. 2014;28(3):120-123

Practical aspects of hormonal therapy for breast cancer

Šárka Lukešová1, Otakar Kopecký2
1 Onkologické oddělení Oblastní nemocnice Náchod, a. s., Ústav klinické mikrobiologie FN a LF UK Hradec Králové
2 Onkologické oddělení Oblastní nemocnice Náchod, a. s., Stomatologická klinika FN a LF UK, Hradec Králové

Hormonal therapy is the oldest and safest clinically proven therapeutic method used in all stages of breast cancer. It is a targeted, individualized



treatment: Four basic treatment modalities, namely ablative, competitive, inhibitive, and additive, have been included in the clinical

practice. It is the preferred treatment for hormone-dependent breast cancers, including visceral involvement, if there is no high risk or evidence

of hormone resistance or if a therapeutic response needs to be achieved rapidly. The article deals with the currently recommended cascade

of hormonal treatment, including basic studies which the recommendation is based on, the side effects, and the possibility of overcoming

hormone resistance with new medicines coming into clinical practice.

Keywords: breast cancer, hormone receptors, hormone resistance

Published: November 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lukešová Š, Kopecký O. Practical aspects of hormonal therapy for breast cancer. Klin Farmakol Farm. 2014;28(3):120-123.
Download citation

References

  1. Keynes G. The life and works of Sir Astley Cooper. St. Bartholomew´s Hosp Rep, 1921.
  2. Beatson GT. On the treatment of inoperable carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896; 2: 104-107. Go to original source...
  3. Schinzinger A. Ueber carcinoma mammae [abstract]. 18th Congress of the German Society for Surgery. Beilage zum Centralblatt fur Chirurgie 1889; 16: 55-56.
  4. Lacassagne A. Hormonal pathogenesis of adenocarcinoma of the breast. Am J Cancer 1936; 27: 217-225. Go to original source...
  5. Jensen EV, Block GE, Smith S, Kyser K, DeSombre ER. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst. Monogr 1971; 34: 55-70. Go to PubMed...
  6. Dahlman-Wright K, Cavailles V, Fuqua SA, et al. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 2006; 58(4): 773-781. Go to original source... Go to PubMed...
  7. Leung YK, Mak P, Hassan S, Ho SM. Estrogen receptor (ER) -beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci 2006; 103(35): 13162-13167. Go to original source... Go to PubMed...
  8. Harvey JM. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481. Go to original source... Go to PubMed...
  9. LHRH-agonists in Early Breast Cancer Overview group, Cuzik J, Ambroisine L, Davidson N, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007; 369: 1711. Go to original source... Go to PubMed...
  10. Hortobagyi GN. Future directions in the endocrine therapy of breast cancer. Breast Cancer Res Treat 200; 80(Suppl. 1): 37-39.
  11. Morris C, Wakeling A. Fulvestrant (Faslodex) - a new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer, 2002; 9: 267-276. Go to original source... Go to PubMed...
  12. Binkhorst L, van Gelder T, Mathijssen RH. Individualization of tamoxifen treatment for breast carcinoma. Clin Pharmacol Ther 2012; 92: 431-413. Go to original source... Go to PubMed...
  13. Karle J, Bolbrinker J, Vogl S, et al. Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer. Breast Cancer Res Treat 2013; 139(2): 553-560. Go to original source... Go to PubMed...
  14. Campos SH. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 2004; 9: 126-136. Go to original source... Go to PubMed...
  15. Tesařová P. Paliativní hormonální léčba karcinomu prsu. Lékařské listy 2013; 22: 15-19.
  16. Petruželka L, Vočka M, Matějů M, Ušiaková Z, Konopásek B. Nové sekvence hormonální léčby metastazujících hormonálně dependentních karcinomů prsu u postmenopauzálních žen. Prague ONCO Journal 2014: 27-30.
  17. BIG 1-98 Collaborative Group, Mourisden H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009; 361: 766-776. Go to original source... Go to PubMed...
  18. Puhalla S, Bhattacharya S, Davidson NE. Hormonal therapy in breast cancer: a model disease for the personalization of cancer care. Mol Oncol 2012; 6: 222-236. Go to original source... Go to PubMed...
  19. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med, 2012; 366(6): 520-259. Go to original source... Go to PubMed...
  20. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009; 27(33): 5529-5537. Go to original source... Go to PubMed...
  21. Delea TE, Hawkes C, Amonkar MM, Lykopoulos K, Johnston S. Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast Cancer. Breast Care (Basel) 2013; 8(6): 429-437. Go to original source... Go to PubMed...
  22. Barrios C, Forbes JF, Jonat W, et al. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol, 2012; 23: 1378-1386. Go to original source... Go to PubMed...
  23. Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014; 106: 1-7. Go to original source...
  24. Robertson JF, Lindemann JP, Lombart-Cussac A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized, FIRST' study. Breast Cancer Res Treat. 2012; 136(2): 503-511. Go to original source... Go to PubMed...
  25. Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012; 367(5): 435-444. Go to original source... Go to PubMed...
  26. Bergh J, Jönsson PE, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012; 30(16): 1919-1925. Go to original source... Go to PubMed...
  27. Svoboda T. Současné možnosti hormonální léčby v terapii karcinomu prsu. Farmakoterapie 2013; 5: 539-548.
  28. Fínek J. Nejčastější nežádoucí účinky chemoterapie a hormonální léčby. Farmakoterapie 2014; speciální příloha Léčba pokročilého karcinomu prsu: 40-45.
  29. Petráková K. Inhibice mTOR jako nová možnost v léčbě karcinomu prsu. Farmakoterapie 2013; 9(2): 149-153.
  30. André F, O'Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014; 15(6): 580-591. Go to original source... Go to PubMed...
  31. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013; 30(10): 870-884. Go to original source... Go to PubMed...
  32. Finn RS, Crown JP, Lang I, et al. Results of a randomized phase 2 study of PD 0332991, a cyclindependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (BC) Cancer Res; 2012; 72(24 Suppl.): 91. Go to original source...
  33. Klein P, Ordentlich P, McCulloch W, Cruickshank S, Rees M, Yardley DA. Characterization of the overall survival benefit in ENCORE 301, a randomized placebo-controlled phase II study of exemestane with and without entinostat in ER+ postmenopausal women with metastatic breast cancer [abstract]. J Clin Oncol. 2012; 30(Suppl): Abstract 567. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.